← Eichor
Study identifier: NCT07480564 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

Condition: Rett Syndrome  ·  Sponsor: Taysha Gene Therapies, Inc.

PhasePhase 3
Planned participants3
Who can joinFemale, 2 Years to 3 Years
Healthy volunteersNo

About this study

The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.

This description comes directly from the study's public registry record.

Talk to the study team

Taysha Gene Therapies Medical Information  ·  833-489-8742  ·  medinfo@tayshagtx.com

Always discuss trial participation with your own doctor first.

Locations (1)

Boston Children's HospitalBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07480564